Interestingly, a high number of PD-1+ tumour-infiltrating lymphocytes is a favorable prognostic factor in DLBCL [107,173], suggesting ongoing anti-lymphoma T cell responses, still with a chance to respond to combinational PD-1/PD-L1 blockade [133] and yet not fully progressed into the immune deserted scenario with poorer clinical outcomes [81]. This evidence concerns the gene CD274 and lymphoma.